Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2005

View Archived Issues

SR-141716 proves active in chronic neuropathic pain

XP-828L reported effective and safe in mild to moderate psoriasis

Treatment intervals of 4-7 days necessary for HuCAL-derived antibody efficacy

MEN-13510: A new selective NK2 receptor antagonist

FBCx reported to improve the lipid profile of obese patients with type 2 diabetes

GSK and Vitae form alliance in hypertension and cardiovascular disorders

KRX-101 enters pivotal phase III and phase IV programs

Phase III study evaluates Xifaxan in prevention of travelers' diarrhea

GTC Biotherapeutics files ATryn response to EMEA

Rigel gives low-down on pipeline

Agents for arthritis and other inflammatory disorders found in patent literature

Tarceva sNDA for pancreatic cancer granted priority review

Novartis and P&G to copromote Enablex in U.S.

European SPIRIT II trial begins enrollment

New treatments for respiratory disorders emerge from recent R&D

Doxycycline shows promise in the treatment of osteoarthritis

Schering AG announces completion of clinical trial with interferon beta-1b in early MS

FTY-720 reduces relapses in patients with relapsing multiple sclerosis

First phase I/II data with HuMax-CD20 in follicular non-Hodgkin's lymphoma

LymPro Test differentiates Alzheimer's from other dementia in pilot study

OSI grants DPP-IV license to Japanese company

IH-901 exerts antimetastatic effects in mice

Waiting period expires for Anadys' collaboration with Novartis

Long-term effects of CRX-675 in a dog model of allergic rhinitis

SPP-301 begins phase III for diabetic nephropathy

FDA approval for Aczone

Update on the antitumor efficacy of TG-4010 in NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...